目的 探讨雷贝拉唑、阿莫西林联合甲硝唑对幽门螺旋杆菌的临床效果。方法 选取2016年1月—2017年12月于中国人民解放军第464医院诊治的幽门螺旋杆菌患者90例进行前瞻性研究，采用随机数字法分为观察组（45例）和对照组（45例），对照组患者给予奥美拉唑、阿莫西林联合甲硝唑，观察组患者给予雷贝拉唑、阿莫西林联合甲硝唑，两组患者均接受治疗4周。比较两组患者临床治疗有效率，腹胀、腹痛、反酸及嗳气的缓解时间及不良反应发生率。结果 观察组患者的有效率为91.11%，对照组患者的治疗有效率为73.33%，差异具有统计学意义（P<0.05）。与对照组相比，观察组患者的腹胀、腹痛、反酸及嗳气缓解时间均显著缩短，差异具有统计学意义（P<0.05）。观察组患者的不良反应发生率为13.33%，对照组患者的不良反应发生率为17.78%，差异无统计学意义。结论 雷贝拉唑、阿莫西林联合甲硝唑对幽门螺旋杆菌的临床治疗效果较好，能够有效改善患者的临床症状，具有积极的临床意义。
Objective To investigate the clinical efficacy of rabeprazole, amoxicillin combined with metronidazolein the treatment of Helicobacter pylori. Methods 90 patients with helicobacter pylori were collected in 464th People's Liberation Army of China from January to December 2017 conducted prospective study, according to random number method divided into observation group (45 cases) and control group (45 cases), the control group was given omeprazole, amoxicillin combined with metronidazole, the observation group was given rabeprazole, amoxicillin combined with metronidazole, the two groups treatment for four weeks, and compared with the clinical effective rate, the abdominal distension, abdominal pain, sour regurgitation and belching time and the incidence of adverse reaction of the two groups. Results The effective rate of the observation group is 91.11%, the effective rate of the control group is 73.33%, the difference was statistically significant (P<0.05). Compared with the control group, the abdominal distension, abdominal pain, sour regurgitation and belching time significantly shortened, the difference was statistically significant (P<0.05). The incidence of adverse reaction of the observation group is 13.33%, the incidence of adverse reaction of the control group is 17.78%, the difference was not statistically significant. Conclusion Rabeprazole, amoxicillin combined with metronidazole with Helicobacter pylori has good clinical efficacy, can effectively improve the patient's clinical symptoms, with positive clinical significance.